The rumors of reported AstraZeneca–Bristol Myers merger discussions provide an opportunity to examine how multiple emerging capabilities may reshape corporate strategy, mergers and acquisitions, and ...

A senior source close to the companies denied any active or historical basis for a transaction, and both firms declined to comment on the denial. Prior speculation centered on preliminary discussions ...

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and ...

Sandoz Inc. and Fougera Pharmaceuticals will settle three Connecticut federal cases, paying $400 million over seven years plus ~$50 million to prior settlors, pending approvals from all participating ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Rumored tie-up implies acquirer skepticism versus target premium, with AstraZeneca shares falling sharply while BMS rose, reflecting concerns about value transfer and integration risk. A major ...

Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts ...

Chinese biotech deal flow is increasingly driven by authentic innovation rather than legacy concerns around imitation and IP ...

In today's Pharmaceutical Executive Daily, a senior source denies reports of merger talks between AstraZeneca and Bristol Myers Squibb, CSPC Pharmaceutical and AstraZeneca form a joint venture for ...

Pharmaceutical Executive spoke with Dr. Richard Graham, chairman and co-founder of TruTechnologies about FDA’s new program ...

Third-party data from distributors and vendors requires explicit controls for file receipt, validation, exception handling, ...